The Bedford, Mass.-based eye condition therapy developer filed with the SEC to confirm the offering with the shares at a par value of $0.0001 per share. The common stock at market close on May 18 prior to the announcement was $6.76 per share, according to the filing.
In a news release, the company said it expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares to be sold under the same terms and conditions. Ocular Therapeutix will sell all shares in the offering and is not offering assurance as to whether or when it may be completed.
Jefferies LLC and Piper Sandler & Co. are acting as joint book-running managers for the ophthalmic insert maker’s offering.